Gene expression-based assays have been introduced into the clinical arena to assist in the diagnosis of poorly differentiated or undifferentiated tumors. The US Food and Drug Administration has cleared the microarray-based Pathwork Tissue of Origin (TOO) Test (Pathwork Diagnostics, Sunnyvale, CA) for the molecular characterization of such challenging specimens. We aimed at verifying the analytic and clinical performance of this test on 43 poorly differentiated and undifferentiated tumor samples, including 6 off-panel cases and 7 cancers of unknown primary (CUP). Our results showed 97% (95% confidence interval, 80.4%-99.8%) agreement between the Pathwork TOO Test result and the complete diagnosis, which included clinical correlations and immunohistochemical staining, after the original diagnosis. We concluded that for off-panel and CUP samples, the tissue type and the cell type may be confounded by the Pathwork TOO Test and that careful clinicopathologic assessment is needed when interpreting results from this helpful ancillary tool for pathologists.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1309/AJCPDQPFO73SSNFR | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
Ann Oncol
February 2016
Division of Medical Oncology
Background: Carboplatin (C) and paclitaxel (P) are standard treatments for carcinoma of unknown primary (CUP). Everolimus, an mTOR inhibitor, exhibits activity in diverse cancer types. We did a phase II trial combining everolimus with CP for CUP.
View Article and Find Full Text PDFA multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.
Am J Surg Pathol
July 2013
Department of Pathology and Laboratory Medicine, University of Tennessee College of Medicine, Memphis, TN 38163, USA.
Metastatic tumors with an uncertain primary site can be a difficult clinical problem. In tens of thousands of patients every year, no confident diagnosis is ever issued, making standard-of-care treatment impossible. Gene expression profiling (GEP) tests currently available to analyze these difficult-to-diagnose tumors have never been directly compared with the diagnostic standard of care, immunochemistry (IHC).
View Article and Find Full Text PDFA gene expression profile test to resolve head & neck squamous versus lung squamous cancers.
Diagn Pathol
March 2013
Pathwork Diagnostics, 595 Penobscot Dr, Redwood City, CA 94063, USA.
Background: The differential diagnosis between metastatic head & neck squamous cell carcinomas (HNSCC) and lung squamous cell carcinomas (lung SCC) is often unresolved because the histologic appearance of these two tumor types is similar. We have developed and validated a gene expression profile test (GEP-HN-LS) that distinguishes HNSCC and lung SCC in formalin-fixed, paraffin-embedded (FFPE) specimens using a 2160-gene classification model.
Methods: The test was validated in a blinded study using a pre-specified algorithm and microarray data files for 76 metastatic or poorly-differentiated primary tumors with a known HNSCC or lung SCC diagnosis.
Gene expression microarray-based assay to determine tumor site of origin in a series of metastatic tumors to the ovary and peritoneal carcinomatosis of suspected gynecologic origin.
Hum Pathol
January 2013
Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Spain.
Article Synopsis
- Determining the origin of primary tumors in ovarian and peritoneal metastases can be challenging, leading to a study involving 25 metastatic tumors to the ovary and 7 cases of peritoneal carcinomatosis suspected to have gynecologic origins.
- The Tissue of Origin-Frozen test, a gene expression-based method, was able to accurately identify the site of origin in more cases compared to traditional immunohistochemical staining techniques.
- The combination of the Tissue of Origin-Frozen test and immunohistochemistry successfully identified the correct tumor origin in 19 out of 22 cases, highlighting its potential usefulness in complicated diagnoses.
Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer.
Diagn Pathol
August 2012
University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Background: Determining the primary site of metastatic cancer with confidence can be challenging. Pathologists commonly use a battery of immunohistochemical (IHC) stains to determine the primary site. Gene expression profiling (GEP) has found increasing use, particularly in the most difficult cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!